Digging into the NGS Information from a Large-Scale South European Population with Metastatic/Unresectable Pancreatic Ductal Adenocarcinoma: A Real-World Genomic Depiction
Authors:
- Dimitrios C. ZiogasDZDimitrios C. Ziogas
- Eirini PapadopoulouEPEirini Papadopoulou
- Helen GogasHGHelen Gogas
- Stratigoula SakellariouSSStratigoula Sakellariou
- Evangellos FelekourasEFEvangellos Felekouras
- Charalampos TheocharopoulosCTCharalampos Theocharopoulos
- Dimitra T. StefanouDSDimitra T. Stefanou
- Maria TheochariMTMaria Theochari
- Ioannis BoukovinasIBIoannis Boukovinas
- Dimitris MatthaiosDimitris Matthaios
- Anna KoumarianouAKAnna Koumarianou
- Eleni ZairiEZEleni Zairi
Open Access
Abstract
Despite ongoing oncological advances, pancreatic ductal adenocarcinoma (PDAC) continues to have an extremely poor prognosis with limited targeted and immunotherapeutic options. Its genomic background has not been fully characterized yet in large-scale populations all over the world. Methods: Replicating a recent study from China, we collected tissue samples from consecutive Greek patients with pathologically-confirmed metastatic/unresectable PDAC and retrospectively investigated their genomic landscape using next generation sequencing (NGS). Findings: From a cohort of 409 patients, NGS analysis was successfully achieved in 400 cases (56.50% males, median age: 61.8 years). Consistent with a previous study, KRAS was the most frequently mutated gene in 81.50% of tested samples, followed by TP53 (50.75%), CDKN2 (8%), and SMAD4 (7.50%). BRCA1/2 variants with on-label indications were detected in 2%, and 87.50% carried a variant associated with off-label treatment (KRAS, ERBB2, STK11, or HRR-genes), while 3.5% of the alterations had unknown/preliminary-studied actionability (TP53/CDKN2A). Most of HRR-alterations were in intermediate- and low-risk genes (CHEK2, RAD50, RAD51, ATM, FANCA, FANCL, FANCC, BAP1), with controversial actionability: 8% harbored a somatic non-BRCA1/2 alteration, 6 cases had a high-risk alteration (PALB2, RAD51C), and one co-presented a PALB2/BRCA2 alteration. Elevated LOH was associated with HRR-mutated status and TP53 mutations while lowered LOH was associated with KRAS alterations. Including TMB/MSI data, the potential benefit from an NGS-oriented treatment was increased from 1.91% to 13.74% (high-MSI: 0.3%, TMB > 10 muts/MB: 12.78%). TMB was slightly increased in females (4.75 vs. 4.46 muts/MB) and in individuals with age > 60 (4.77 vs. 4.40 muts/MB). About 28.41% showed PD-L1 > 1% either in tumor or immune cells, 15.75% expressed PD-L1 ≥ 10%, and only 1.18% had PD-L1 ≥ 50%. This is the largest depiction of real-world genomic characteristics of European patients with PDAC, which offers some useful clinical and research insights.Keywords
This publication has 51 references indexed in Scilit:
- Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint InhibitorsJournal of Thoracic Oncology, 2017
- Integrated Genomic Characterization of Pancreatic Ductal AdenocarcinomaCancer Cell, 2017
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)Cancer Discovery, 2017
- KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic AdenocarcinomaClinical and Translational Gastroenterology, 2016
- Dilemma of first line regimens in metastatic pancreatic adenocarcinomaWorld Journal of Gastroenterology, 2016
- Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) TrialClinical Cancer Research, 2015
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine, 2015
- Pancreatic cancer genomes reveal aberrations in axon guidance pathway genesNature, 2012
- Mutant p53: one name, many proteinsGenes & Development, 2012
- Blinded by the Light: The Growing Complexity of p53Cell, 2009